Treating Bleeding and Improving Life Quality in Hereditary Hemorrhagic Telangiectasia
Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia
This project explores if a medication called bevacizumab can help adults with Hereditary Hemorrhagic Telangiectasia (HHT) by reducing bleeding and improving their daily lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11109583 on NIH RePORTER |
What this research studies
Hereditary Hemorrhagic Telangiectasia (HHT) is a lifelong bleeding disorder with no approved treatments, causing fragile blood vessels that lead to severe nosebleeds and gut bleeding. This often results in anemia and a lower quality of life. Researchers have seen promising results using a medication called bevacizumab, which targets a growth factor that contributes to these fragile vessels. This project will conduct a clinical trial to confirm if bevacizumab can effectively reduce bleeding, decrease the need for transfusions, and improve how patients feel day-to-day.
Who could benefit from this research
Good fit: Ideal candidates are adults aged 21 and older who have Hereditary Hemorrhagic Telangiectasia (HHT) and are dependent on iron infusions or blood transfusions due to chronic bleeding.
Not a fit: Patients who do not experience significant bleeding or are not dependent on transfusions or iron infusions may not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this medication could significantly reduce bleeding episodes, lessen the need for blood transfusions and iron infusions, and greatly improve the daily lives of people with HHT.
How similar studies have performed: Previous observational work has shown that bevacizumab can reduce transfusions and improve hemoglobin levels in HHT patients, but this trial aims to provide more definitive evidence.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Al-Samkari, Hanny T — Massachusetts General Hospital
- Study coordinator: Al-Samkari, Hanny T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.